, Volume 38, Supplement 1, pp 25–31 | Cite as

Trimipramine, Anxiety, Depression and Sleep

  • J. C. Pecknold
  • L. Luthe


The presence of mixed symptoms of anxiety and depression are well known to every clinician. Panic, generalised anxiety and obsessive-compulsive disorder all have considerable overlap with major depressive illness. Factor analysis of anxiety and depression symptoms has sought to predict response to treatment as well as to establish a diagnosis. Sleep disturbances are important concomitants of both syndromes. The analysis of the architecture and phasing of sleep stages has been proposed as a biological marker to separate anxiety and depression. The modification of REM and delta sleep has been correlated with antidepressant action.

The earliest studies of trimipramine noted antidepressant, anxiolytic and hypnotic effects. Further observations have shown this drug to have atypical effects on REM sleep. In addition, despite its structural similarity to other tricyclic antidepressants, its pharmacological profile in animals is very different: there is no synaptosomal reuptake of serotonin or nor adrenaline, and no desensitisation of β-adrenoceptors after long term administration.

A series of studies was carried out on 99 patients. Admission criteria for the studies specified a minimum score of 20 on the Anxiety Status Inventory as well as the presence of moderate depression. An uncontrolled trial demonstrated the anxiolytic efficacy of trimipramine. Further controlled trials showed superior anxiolytic efficacy of trimipramine to amitriptyline and doxepin with comparable anxiolytic efficacy of trimipramine with maprotiline. All agents had equal antidepressant effects.


Amitriptyline Doxepin Maprotiline Trimipramine Zimelidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akiskal H. Characterology manifestations of affective disorders: toward a new conceptualization. Integrative Psychiatry, May–June: 83–88, 1984Google Scholar
  2. Andreasen NC, Scheftner W, Reich T, Hirschfeld RM, Endicott J, et al. The validation of the concept of endogenous depression. A family study approach. Archives of General Psychiatry 43: 246–251, 1986CrossRefGoogle Scholar
  3. Assalian P, Rosengarten MD, Phillips R. A comparative trial of the antidepressant, anxiolytic and cardiovascular effects of trimipramine and doxepin in depressed hospitalised patients. Journal of Clinical Psychiatry 46: 90–94, 1985PubMedGoogle Scholar
  4. Carlsson A, Lindqvist M. Effects of antidepressant agents in the synthesis of brain monoamines. Journal of Neurological Transactions 43: 73–91, 1978CrossRefGoogle Scholar
  5. Carney MWP, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of ECT response. British Journal of Psychiatry 111: 659–674, 1965PubMedCrossRefGoogle Scholar
  6. Clancy J, Noyes Jr R, Hoenk PR, Slymen DJ. Secondary depression in anxiety neurosis. Journal of Nervous and Mental Disorders 166: 846–850, 1978CrossRefGoogle Scholar
  7. Cournoyer G, de Montigny C, Ouellette J, Langlois R, Elie R, et al. A comparative double-blind study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. Journal of Clinical Psychopharmacology 7: 385–393, 1987PubMedCrossRefGoogle Scholar
  8. Dubé S, Kumar N, Ettedgur E, Pohl R, Jones D, et al. Cholinergic REM-induction response: separation of anxiety and depression. Biological Psychiatry 20: 408–418, 1985PubMedCrossRefGoogle Scholar
  9. Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. American Journal of Medicine 80 (Suppl. 3B): 1–9, 1986PubMedCrossRefGoogle Scholar
  10. Erutka I, Ban TA, Lehmann HE. The effect of trimipramine on newly admitted depressed patients. In Lehmann et al. (Eds) Trimipramine, a new anti-depressant, pp. 59–64, Phoenix Printing, Montreal, 1964Google Scholar
  11. Fawcett J, Kravits HM. Anxiety syndromes and their relationship to depressive illness. Journal of Clinical Psychiatry 44: 8–11, 1983PubMedGoogle Scholar
  12. Gardner CR. Pharmacological studies of the role of serotonin in animal models of anxiety. In Green AR (Ed.) Neuropharmacology of serotonin, pp. 281–235, Oxford University Press, 1985Google Scholar
  13. Gray JA. The neuropsychology of anxiety: an inquiry into the functions of the septo-hippocampal system. Oxford University Press, New York, 1982Google Scholar
  14. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23: 56–62, 1960CrossRefGoogle Scholar
  15. Hauser K, Olpe HR, Jones RSG. Trimipramine, a tricyclic antidepressant exerting atypical actions on the central noradrenergic system. European Journal of Pharmacology 3: 23–30, 1985CrossRefGoogle Scholar
  16. Hunter JW, Owen S, Ekis A, et al. A controlled cross-over study of trimipramine and amylobarbitone. British Journal of Psychiatry 113: 667–670, 1967PubMedCrossRefGoogle Scholar
  17. Iversen SD. 5-HT and anxiety. Neuropharmacology 23: 1553–1560, 1984PubMedCrossRefGoogle Scholar
  18. Juillet P, Dorey R, Coreau P, et al. Action de la trimeproprimine (7162 RP) dans certains états névrotiques. Annales de Medicopsychologie 120: 586–592, 1962Google Scholar
  19. Kahn RJ, McNair DM, Lipman RS, Covi L, Rickeis K, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Archives of General Psychiatry 43: 79–85, 1986PubMedCrossRefGoogle Scholar
  20. Kiloh LG, Garside RF. The independence of neurotic depression and endogenous depression. British Journal of Psychiatry 109: 451–463, 1963PubMedCrossRefGoogle Scholar
  21. Klerman GL. The scientific status of neurotic depression. Psychopathology 18: 167–173, 1985PubMedCrossRefGoogle Scholar
  22. Lambert PA, Guyotat J, Charriot G. La trimeproprimine (7162 RP) un nouvel antidepresseur a proprietes sedatives et tranquillisantes. Annales de Medico-psychologie 2: 713–717, 1961Google Scholar
  23. Leckman JF, Weissman MM, Merikangas KR, Pauls DL, Prusoff BA. Panic disorder and major depression. Increased risk of depression, alcoholism, panic, and phobic disorders in families of depressed probands with panic disorder. Archives of General Psychiatry 40: 1055–1060, 1983Google Scholar
  24. Lehmann HE. The clinician’s view of anxiety and depression. Journal of Clinical Psychiatry 44: 3–7, 1983PubMedGoogle Scholar
  25. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, et al. Psychopharmacologic validation of atypical depression. Journal of Clinical Psychiatry 45: 22–25, 1984PubMedGoogle Scholar
  26. Overall JE, Hollister L, Johnson M, et al. Nosology of depression and differential response to drugs. Journal of the American Medical Association 195: 946–948, 1966PubMedCrossRefGoogle Scholar
  27. Pecknold JC. Anxiety depressions. In McClure DJ (Ed.) Unmasking the faces of depression, Rhône-Poulenc, in pressGoogle Scholar
  28. Pecknold JC, Ananth J, Van den Steen N, Krishnappa U. Trimipramine in the treatment of anxious-depressed outpatients. Current Therapeutic Research 23: 94–100, 1978Google Scholar
  29. Pecknold JC, McClure DJ, Elie R, et al. Trimipramine and amitriptyline: comparison in anxiety-depression. Current Therapeutic Research 26: 497–504, 1979Google Scholar
  30. Pecknold JC, Familamiri P, McClure DJ, Elie R, Chang H. Trimipramine and maprotiline: antidepressant, anxiolytic and cardiotoxic comparison. Journal of Clinical Psychiatry 46: 166–171, 1985PubMedGoogle Scholar
  31. Pecknold JC, McClure DJ, Chang H. Zimeldine, comparative study in depression. Current Therapeutic Research 38: 808–816, 1985Google Scholar
  32. Rickels K, Gordon PE, Weise CC. Amitriptyline and trimipramine in neurotic depressed outpatients: a collaborative study. American Journal of Psychiatry 12: 126–135, 1970Google Scholar
  33. Rifkin A, Saraf K, Kane J, et ai. A comparison of trimipramine and imipramine: a controlled study. Journal of Clinical Psychiatry 41: 124–129, 1960Google Scholar
  34. Roth M, Gurney C, Garside RF, Kerr TA. Studies in the classification of affective disorders: the relationship between anxiety states and depressive illness — I. British Journal of Psychiatry 121: 147–161, 1972PubMedCrossRefGoogle Scholar
  35. Rouleau Y. L’emploi de la trimipramine dans les états dépressifs. In Lehmann et al. (Eds) Trimipramine, a new antidepressant, pp. 65–68, Phoenix Printing, Montreal, 1964Google Scholar
  36. Sargent W. ‘Mood lability and reactivity are characteristic of atypical depression.’ Drugs in the treatment of depression. British Medical Journal 1: 225–227, 1960CrossRefGoogle Scholar
  37. Sigwald J, Henne M, Bouttier D, Raymondeau C, Quetin A. Psychiatric and neurological activity of a new phenothiazine. Presse Médicale 87: 2011, 1956Google Scholar
  38. Temple DL, Yucca FD. Current perspectives on the mechanism of action of buspirone. Abstracts of the 15th CINP Meeting, San Juan, Puerto Rico, Dec 14–17, 1986, Abstract, p. 154Google Scholar
  39. Vidal G, Vidal B, Valery MB. Essais cliniques de la trimeproprimine (7162 RP). Annales de Medico-psychologie 2: 422, 1962Google Scholar
  40. Ware JC, Brown FW, Moorad PJ, et al. Comparison of trimipramine and imipramine in depressed insomniac patients. Sleep Research 14: 65, 1985Google Scholar
  41. West ED, Dally PJ. Effects of iproniazid in depressive syndromes. British Medical Journal 1: 1491–1499, 1959PubMedCrossRefGoogle Scholar
  42. Zung WWK. A rating instrument for anxiety disorders. Psychosomatics 12: 371–379, 1975Google Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • J. C. Pecknold
    • 1
  • L. Luthe
    • 1
  1. 1.Douglas Research CenterDouglas HospitalVerdunCanada

Personalised recommendations